|
1
|
Ikehata M, Ogawa M, Yamada Y, Tanaka S,
Ueda K and Iwakawa S: Different effects of epigenetic modifiers on
the cytotoxicity induced by 5-fluorouracil, irinotecan or
oxaliplatin in colon cancer cells. Biol Pharm Bull. 37:67–73. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang H, Zhang L, Yang X, Jin Y, Pei S,
Zhang D, Zhang H, Zhou B, Zhang Y and Lin D: PUMA mediates the
combinational therapy of 5-FU and NVP-BEZ235 in colon cancer.
Oncotarget. 6:14385–14398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen J, Lu H, Yan D, Cui F, Wang X, Yu F,
Xue Y, Feng X, Wang J, Wang X, et al: PAK6 increase chemoresistance
and is a prognostic marker for stage II and III colon cancer
patients undergoing 5-FU based chemotherapy. Oncotarget. 6:355–367.
2015.PubMed/NCBI
|
|
4
|
Montazami N, Andish M Kheir, Majidi J,
Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar MA,
Khaze V, Mansoori B, et al: siRNA-mediated silencing of MDR1
reverses the resistance to oxaliplatin in SW480/OxR colon cancer
cells. Cell Mol Biol (Noisy-le-grand). 61:98–103. 2015.PubMed/NCBI
|
|
5
|
Chen MC, Lee NH, Ho TJ, Hsu HH, Kuo CH,
Kuo WW, Lin YM, Tsai FJ, Tsai CH and Huang CY: Resistance to
irinotecan (CPT-11) activates epidermal growth factor
receptor/nuclear factor kappa B and increases cellular metastasis
and autophagy in LoVo colon cancer cells. Cancer Lett. 349:51–60.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan S, Peng X, Peng W, Zhao Y and Wei Y:
Enhancement of oxaliplatin-induced cell apoptosis and tumor
suppression by 3-methyladenine in colon cancer. Oncol Lett.
9:2056–2062. 2015.PubMed/NCBI
|
|
7
|
Nemunaitis J, Cox J, Meyer W, Courtney A
and Mues G: Irinotecan hydrochloride (CPT-11) resistance identified
by K-ras mutation in patients with progressive colon cancer after
treatment with 5-fluorouracil (5-FU). Am J Clin Oncol. 20:527–529.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo C, Yuan D, Li X, Yao W, Luo G, Chi X,
Li H, Irwin MG, Xia Z and Hei Z: Propofol attenuated acute kidney
injury after orthotopic liver transplantation via inhibiting gap
junction composed of connexin 32. Anesthesiology. 122:72–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He B, Tong X, Wang L, Wang Q, Ye H, Liu B,
Hong X, Tao L and Harris AL: Tramadol and flurbiprofen depress the
cytotoxicity of cisplatin via their effects on gap junctions. Clin
Cancer Res. 15:5803–5810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gielen PR, Aftab Q, Ma N, Chen VC, Hong X,
Lozinsky S, Naus CC and Sin WC: Connexin43 confers Temozolomide
resistance in human glioma cells by modulating the mitochondrial
apoptosis pathway. Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le HT, Sin WC, Lozinsky S, Bechberger J,
Vega JL, Guo XQ, Sáez JC and Naus CC: Gap junction intercellular
communication mediated by connexin43 in astrocytes is essential for
their resistance to oxidative stress. J Biol Chem. 289:1345–1354.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu M, Zhang C, Li L, Dong S, Zhang N and
Tong X: Cx43 reverses the resistance of A549 lung adenocarcinoma
cells to cisplatin by inhibiting EMT. Oncol Rep. 31:2751–2758.
2014.PubMed/NCBI
|
|
13
|
Wang Q, You T, Yuan D, Han X, Hong X, He
B, Wang L, Tong X, Tao L and Harris AL: Cisplatin and oxaliplatin
inhibit gap junctional communication by direct action and by
reduction of connexin expression, thereby counteracting cytotoxic
efficacy. J Pharmacol Exp Ther. 333:903–911. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Y, Liu B, Wang Q, Yuan D, Yang Y,
Hong X, Wang X and Tao L: Propofol depresses the cytotoxicity of
X-ray irradiation through inhibition of gap junctions. Anesth
Analg. 112:1088–1095. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan D, Wang Q, Wu D, Yu M, Zhang S, Li L,
Tao L and Harris AL: Monocyte-endothelial adhesion is modulated by
Cx43-stimulated ATP release from monocytes. Biochem Biophys Res
Commun. 420:536–541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo C, Yuan D, Yao W, Cai J, Zhou S, Zhang
Y and Hei Z: Dexmedetomidine protects against apoptosis induced by
hypoxia/reoxygenation through the inhibition of gap junctions in
NRK-52E cells. Life Sci. 122:72–77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong X, Wang Q, Yang Y, Zheng S, Tong X,
Zhang S, Tao L and Harris AL: Gap junctions propagate opposite
effects in normal and tumor testicular cells in response to
cisplatin. Cancer Lett. 317:165–171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia-Rodríguez L, Pérez-Torras S, Carrió
M, Cascante A, García-Ribas I, Mazo A and Fillat C: Connexin-26 is
a key factor mediating gemcitabine bystander effect. Mol Cancer
Ther. 10:505–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanson M, Marcaud V, Robin E, Valéry C,
Sturtz F and Zalc B: Connexin 43-mediated bystander effect in two
rat glioma cell models. Cancer Gene Ther. 9:149–155. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vrionis FD, Wu JK, Qi P, Waltzman M,
Cherington V and Spray DC: The bystander effect exerted by tumor
cells expressing the herpes simplex virus thymidine kinase (HSVtk)
gene is dependent on connexin expression and cell communication via
gap junctions. Gene Ther. 4:577–585. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gonzalez-Nieto D, Li L, Kohler A, Ghiaur
G, Ishikawa E, Sengupta A, Madhu M, Arnett JL, Santho RA, Dunn SK,
et al: Connexin-43 in the osteogenic BM niche regulates its
cellular composition and the bidirectional traffic of hematopoietic
stem cells and progenitors. Blood. 119:5144–5154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Autsavapromporn N, de Toledo SM, Little
JB, Jay-Gerin JP, Harris AL and Azzam EI: The role of gap junction
communication and oxidative stress in the propagation of toxic
effects among high-dose α-particle-irradiated human cells. Radiat
Res. 175:347–357. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Segretain D, Decrouy X, Dompierre J,
Escalier D, Rahman N, Fiorini C, Mograbi B, Siffroi JP, Huhtaniemi
I, Fenichel P and Pointis G: Sequestration of connexin43 in the
early endosomes: An early event of Leydig cell tumor progression.
Mol Carcinog. 38:179–187. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Cheng L, Wang LJ, Liu HC, Li L, Wang
XL and Geng MY: Cell surface sialic acid inhibits Cx43 gap junction
functions in constructed Hela cancer cells involving in sialylated
N-cadherin. Mol Cell Biochem. 344:241–251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin Q, Balasubramanian K, Fan D, Kim SJ,
Guo L, Wang H, Bar-Eli M, Aldape KD and Fidler IJ: Reactive
astrocytes protect melanoma cells from chemotherapy by sequestering
intracellular calcium through gap junction communication channels.
Neoplasia. 12:748–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matesic DF, Sidorova TS, Burns TJ, Bell
AM, Tran PL, Ruch RJ and May SW: p38 MAPK activation, JNK
inhibition, neoplastic growth inhibition, and increased gap
junction communication in human lung carcinoma and Ras-transformed
cells by 4-phenyl-3-butenoic acid. J Cell Biochem. 113:269–281.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aftab Q, Sin WC and Naus CC: Reduction in
gap junction intercellular communication promotes glioma migration.
Oncotarget. 6:11447–11464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grossi V, Peserico A, Tezil T and Simone
C: p38alpha MAPK pathway: A key factor in colorectal cancer therapy
and chemoresistance. World J Gastroenterol. 20:9744–9758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martinez-Balibrea E, Martínez-Cardús A,
Ginés A, de Porras V Ruiz, Moutinho C, Layos L, Manzano JL, Bugés
C, Bystrup S, Esteller M and Abad A: Tumor-related molecular
mechanisms of oxaliplatin resistance. Mol Cancer Ther.
14:1767–1776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Westover D, Ling X, Lam H, Welch J, Jin C,
Gongora C, Del Rio M, Wani M and Li F: FL118, a novel camptothecin
derivative, is insensitive to ABCG2 expression and shows improved
efficacy in comparison with irinotecan in colon and lung cancer
models with ABCG2-induced resistance. Mol Cancer. 14:922015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sovadinova I, Babica P, Böke H, Kumar E,
Wilke A, Park JS, Trosko JE and Upham BL: Phosphatidylcholine
specific PLC-induced dysregulation of gap junctions, a robust
cellular response to environmental toxicants and prevention by
resveratrol in a rat liver cell model. PloS One. 10:e01244542015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong L, Yang X, Gu W, Zhao K, Ge H, Zhou J
and Bai X: Connexin 43 mediates PFOS-induced apoptosis in
astrocytes. Chemosphere. 132:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Igarashi I, Maejima T, Kai K, Arakawa S,
Teranishi M and Sanbuissho A: Role of connexin 32 in acetaminophen
toxicity in a knockout mice model. Exp Toxicol Pathol. 66:103–110.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lawrence TS, Rehemtulla A, Ng EY, Wilson
M, Trosko JE and Stetson PL: Preferential cytotoxicity of cells
transduced with cytosine deaminase compared to bystander cells
after treatment with 5-flucytosine. Cancer Res. 58:2588–2593.
1998.PubMed/NCBI
|
|
35
|
Sirnes S, Bruun J, Kolberg M, Kjenseth A,
Lind GE, Svindland A, Brech A, Nesbakken A, Lothe RA, Leithe E and
Rivedal E: Connexin43 acts as a colorectal cancer tumor suppressor
and predicts disease outcome. Int J Cancer. 131:570–581. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aasen T, Hodgins MB, Edward M and Graham
SV: The relationship between connexins, gap junctions, tissue
architecture and tumour invasion, as studied in a novel in vitro
model of HPV-16-associated cervical cancer progression. Oncogene.
22:7969–7980. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bernzweig J, Heiniger B, Prasain K, Lu J,
Hua DH and Nguyen TA: Anti-breast cancer agents, quinolines,
targeting gap junction. Med Chem. 7:448–453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gee J, Tanaka M and Grossman HB: Connexin
26 is abnormally expressed in bladder cancer. J Urol.
169:1135–1137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leithe E, Sirnes S, Omori Y and Rivedal E:
Downregulation of gap junctions in cancer cells. Crit Rev Oncog.
12:225–256. 2006. View Article : Google Scholar : PubMed/NCBI
|
